Hepatitis B virus (HBV) infection is a major public health problem. Successful clearance of the virus depends on a complex interaction between the virus and the host immune response.
This study was designed to estimation granulocyte macrophage-colony stimulating factor (GM-CSF) in HBV infected patients and individuals vaccinated with recombinant HB vaccine.
Study groups were classified into patient group 31(15 acute (AH) and 16 chronic (CH)), 33 vaccinated group (20 responder (RD) and 13 Non-responder (NRD)) and 16 healthy control (HC) during May to November 2007. Blood samples were taken from patients and hospitals staffs to detection hepatitis B surface antigen(HBsAg), anti-hepatitis B core antibody(IgM)(Anti-HBc Ab(IgM), anti hepatitis B surface antibody) (Anti-HBs Ab), GM-CSF level in serum by enzyme linked immunosorbent assay (ELISA) test.
A highly significant elevation (p<0.001) of GM-CSF level was reported in AH patients compared to the CH patients and HN controls, according to F-test, while in CH patients the elevation was not significant as compared to HN control (p>0.05) according to LSD- test. The level of GM-CSF also significantly higher (p<0.05) in RD at age ≥30 years than NRD and HN groups by F-test. Also a significant differences was recorded when compared between HN versus RD and RD versus NRD (P<0.027) and (P<0.023) respectively.
In this study highly significant elevation of GM-CSF levels was observed in AH patients compared with CH patients and healthy control. GM-CSF level also significantly higher in RD at age ≥30 years than NRD and HN group